Menu

Wolbachia-Laced Mosquitoes to Be Released for Population Control

The US government has approved the deployment of the lab-raised insects to eliminate the Zika- and dengue-transmitting Asian tiger mosquito.

Nov 7, 2017
Katarina Zimmer

Aedes albopictus ISTOCK, GORDZAMThe US Environmental Protection Agency (EPA) has given permission to a biotechnology startup to release mosquitoes into the environment that have been designed to eradicate wild populations of disease-carrying mosquitoes, Nature News reports.

The target is the Asian tiger mosquito Aedes albopictus, a vector for Zika virus—which began to spread in the U.S. last year—as well as dengue and yellow fever. The startup MosquitoMate has designed “killer” tiger mosquitoes by infecting males with the bacterium Wolbachia pipientis. When these treated males mate with wild female mosquitoes that don’t carry the same Wolbachia strain, the resulting eggs die.

According to Nature News, the EPA hasn’t officially announced the release of the insects yet, which will be limited to 20 states. These exclude the southeastern US states, despite harboring a greater concentration of mosquito populations, because field trials have not been conducted in those climates. Instead, the approved states are similar to New York, Kentucky, and California, where trials took place.  

MosquitoMate has launched a field trial of Wolbachia-treated mosquitoes in Florida, but with the A. aegypti species.

David O’Brochta, an entomologist at the University of Maryland, tells Nature: “It’s a non-chemical way of dealing with mosquitoes,” he says, “I’m glad to see it pushed forward, as I think it could be potentially really important.”

Designing lab mosquitoes to eradicate wild populations has been trialed multiple times in Brazil, which was hard hit by the Zika epidemic in 2015, and other countries. There, the company Oxitec has successfully tested modified A. aegypti mosquitoes—which also transmit Zika—such that a deadly gene will be passed on to any offspring once they mate in the wild. 

See “GM Mosquitoes Closer to Release in U.S.

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.